{"id":293427,"date":"2024-06-19T00:00:00","date_gmt":"2024-06-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrmd0028-2024-biopharma-chronic-kidney-disease-current-treatment-current-treatment-physician\/"},"modified":"2026-04-22T17:15:11","modified_gmt":"2026-04-22T17:15:11","slug":"cutrmd0028-2024-biopharma-chronic-kidney-disease-current-treatment-current-treatment-physician-insights-chronic-kidney","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrmd0028-2024-biopharma-chronic-kidney-disease-current-treatment-current-treatment-physician-insights-chronic-kidney\/","title":{"rendered":"Chronic Kidney Disease &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Chronic Kidney Disease (US)"},"content":{"rendered":"<div>\n<p style=\"\">Chronic kidney disease (<abbr title=\"chronic kidney disease\">CKD<\/abbr>) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors are cornerstones of <abbr title=\"chronic kidney disease\">CKD<\/abbr> treatment. <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors are emerging as the next standard-of-care therapy for the treatment of <abbr title=\"chronic kidney disease\">CKD<\/abbr>. AstraZeneca\u2019s Farxiga and Eli Lilly\u2019s Jardiance are approved for treatment of <abbr title=\"chronic kidney disease\">CKD<\/abbr> regardless of diabetes status. Johnson &#038; Johnson\u2019s Invokana is approved for treatment of diabetic kidney disease, a subpopulation of <abbr title=\"chronic kidney disease\">CKD<\/abbr>. The renoprotective benefits demonstrated by <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors in different dedicated <abbr title=\"chronic kidney disease\">CKD<\/abbr> outcomes trials increased the popularity of this class among U.S. nephrologists. In 2021, the <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approved Bayer\u2019s Kerendia, a novel selective nonsteroidal <abbr title=\"mineralocorticoid receptor antagonist\">MRA<\/abbr>, for the treatment of <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients with type 2 diabetes. Kerendia is gradually garnering patient share among diabetic kidney disease patients. This report analyzes the dynamics of the <abbr title=\"chronic kidney disease\">CKD<\/abbr> therapy market, with focus on treatment strategies for <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients in different disease stages and factors that influence treatment decisions.<\/p>\n<\/div>\n<div>\n<p style=\"\"><strong>Questions answered <\/strong><\/p>\n<\/div>\n<ul class=\"BulletListStyle1 BCX0 SCXP107087406 round-bullets\">\n<li>What are U.S. specialists\u2019 perceptions regarding the diagnosis and treatment of <abbr title=\"chronic kidney disease\">CKD<\/abbr>?<\/li>\n<li>How do U.S. nephrologists treat <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients today? What are the choices of therapy by stage of <abbr title=\"chronic kidney disease\">CKD<\/abbr>?<\/li>\n<li>What patient shares do the antihypertensive agents and <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors garner among <abbr title=\"chronic kidney disease\">CKD<\/abbr> patients by line of therapy?<\/li>\n<li>What impact has the entry of <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors had in the <abbr title=\"chronic kidney disease\">CKD<\/abbr> market? In which <abbr title=\"chronic kidney disease\">CKD<\/abbr> stages are <abbr title=\"sodium-glucose co-transporter-2\">SGLT-2<\/abbr> inhibitors most prescribed?<\/li>\n<li>What are the recent and anticipated changes in <abbr title=\"chronic kidney disease\">CKD<\/abbr> treatment practices?<\/li>\n<\/ul>\n<div>\n<p style=\"\"><strong>Product description<\/strong><\/p>\n<\/div>\n<div>\n<p style=\"\">Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-293427","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-kidney-disease","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293427\/revisions"}],"predecessor-version":[{"id":575945,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/293427\/revisions\/575945"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=293427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}